Kaufmann, Paul
Bergmann, Andreas
Melander, Olle
Funding for this research was provided by:
Swedish Heart- and Lung Foundation
The Swedish Research Council
European Research Council (ERC-AdG-2019-885003)
Article History
Received: 14 April 2021
Accepted: 23 July 2021
First Online: 4 August 2021
Competing interests
: P.K. is employed by PAM Theragnostics GmbH, A.B. has shares in and is managing director of PAM Theragnostics GmbH. A.B. has shares in and is CEO of Sphingotec GmbH, the company having patent rights on the sphingotest bio-ADM assay. O.M. declares to have neither disclosures nor financial or non-financial competing interests.